
This content was machine translated.
About RNATICS GmbH
RNATICS develops medicines based on short nucleic acid molecules, so-called oligonucleotides, that target disease-causing RNAs in tissue-resident macrophages. This novel delivery mechanism enables access to organs that have previously been inaccessible for nucleic acid therapies, opening up significant therapeutic potential in many diseases. We plan to start the first clinical trial (Phase I) of our lead candidate, RCS-21, for the treatment of fibrotic lung disease following viral infections (e.g. COVID-19) in spring 2024.
More like this
